cDNA for human methylenetetrahydrofolate reductase
OwnerRima Rozen, Philippe Goyetteinventors
Life of this patent
Estimating the term…
Abstract
Provided herein is a heretofore unknown isolated nucleic acid molecule which encodes human methylenetetrahydrofolate reducatase, along with an amino acid sequence of methylenetetrahydrofolate reductase, and a cDNA probe for human methylenetetrahydrofolate reductase. Also provided are a molecule description of mutations in humans resulting in a phenotype having reduced levels of methylenetetrahydrofolate reductase, and methods of diagnosing methylenetetrahydrofolate reductase deficiency in a human.
Claims15
A method for treating an individual having an MTHFR allele variant correlated to increased or decreased toxicity of a treatment, said method comprising:
- (a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity, and said variant being correlated to increased or decreased toxicity to a treatment for a disorder selected from the group consisting of cardiovascular disorders, coronary and arterial disorders, osteoporosis, and neurological disorders;
- and
- (b) administering said treatment to said individual having said MTHFR allele variant.
A method for treating an individual having an MTHFR allele variant correlated to increased or decreased toxicity of a treatment, said method comprising:
- (a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity, and said variant being correlated to increased or decreased toxicity to a treatment selected from the group consisting of antibiotics and antiepileptic agents;
- and
- (b) administering said treatment to said individual having said MTHFR allele variant.
A method for selecting a treatment that has increased or decreased toxicity in an individual having an MTHFR allele variant, said method comprising:
- (a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity, and said variant being correlated to increased or decreased toxicity to a treatment for a disorder selected from the group consisting of cardiovascular disorders, coronary and arterial disorders, osteoporosis, and neurological disorders;
- and
- (b) selecting a treatment known to have increased or decreased drug toxicity in an individual having said MTHFR allele, wherein said treatment is for a disorder selected from the group consisting of cardiovascular disorders, coronary and arterial disorders, osteoporosis, and neurological disorders.
A method for selecting a treatment that has increased or decreased toxicity in an individual having an MTHFR allele variant, said method comprising:
- (a) analyzing a nucleic acid sample obtained from said individual to determine whether said sample comprises at least one MTHFR allele variant, said variant leading to a decrease in MTHFR activity, and said variant being correlated to increased or decreased toxicity to a treatment selected from the group consisting of antibiotics and antiepileptic agents;
- and
- (b) selecting a treatment known to have increased or decreased drug toxicity in an individual having said MTHFR allele, wherein said treatment is selected from the group consisting of antibiotics and antiepileptic agents.
A method for identifying an individual having an MTHFR allele variant correlated to increased or decreased toxicity of a treatment, said method comprising analyzing a nucleic acid sample obtained from an individual to determine whether said sample comprises at least one MTHFR allele variant correlated to increased or decreased toxicity of a treatment for a disorder selected from the group consisting of cardiovascular disorders, coronary and arterial disorders, osteoporosis, and neurological disorders, wherein said MTHFR allele variant leads to a decrease in MTHFR activity.
A method for identifying an individual having an MTHFR allele variant correlated to increased or decreased toxicity of a treatment, said method comprising analyzing a nucleic acid sample obtained from an individual to determine whether said sample comprises at least one MTHFR allele variant correlated to increased or decreased toxicity of a treatment selected from the group consisting of antibiotics and antiepileptic agents, wherein said MTHFR allele variant leads to a decrease in MTHFR activity.
Dependencies are inferred from the claim text.